LTPA2017035I1 - Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu - Google Patents

Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Info

Publication number
LTPA2017035I1
LTPA2017035I1 LTPA2017035C LTPA2017035C LTPA2017035I1 LT PA2017035 I1 LTPA2017035 I1 LT PA2017035I1 LT PA2017035 C LTPA2017035 C LT PA2017035C LT PA2017035 C LTPA2017035 C LT PA2017035C LT PA2017035 I1 LTPA2017035 I1 LT PA2017035I1
Authority
LT
Lithuania
Prior art keywords
morphine
antibody
treatment
combination
Prior art date
Application number
LTPA2017035C
Other languages
English (en)
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2017035(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of LTPA2017035I1 publication Critical patent/LTPA2017035I1/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
LTPA2017035C 2009-08-14 2017-10-31 Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu LTPA2017035I1 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14
EP10747168.2A EP2464382B1 (en) 2009-08-14 2010-08-12 Combination therapy of an afucosylated cd20 antibody with bendamustine
PCT/EP2010/004939 WO2011018224A1 (en) 2009-08-14 2010-08-12 Combination therapy of an afucosylated cd20 antibody with bendamustine

Publications (1)

Publication Number Publication Date
LTPA2017035I1 true LTPA2017035I1 (lt) 2017-11-27

Family

ID=41351729

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP10747168.2T LT2464382T (lt) 2009-08-14 2010-08-12 Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu
LTPA2017035C LTPA2017035I1 (lt) 2009-08-14 2017-10-31 Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP10747168.2T LT2464382T (lt) 2009-08-14 2010-08-12 Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu

Country Status (34)

Country Link
US (4) US20110165151A1 (lt)
EP (1) EP2464382B1 (lt)
JP (3) JP5646626B2 (lt)
KR (1) KR101425736B1 (lt)
CN (2) CN107261138A (lt)
AR (1) AR077866A1 (lt)
AU (1) AU2010281866B2 (lt)
BR (1) BR112012002855A2 (lt)
CA (1) CA2769674C (lt)
CL (1) CL2012000391A1 (lt)
CR (1) CR20120036A (lt)
CY (2) CY1119251T1 (lt)
DK (1) DK2464382T3 (lt)
ES (1) ES2630158T3 (lt)
HK (1) HK1245145A1 (lt)
HR (1) HRP20170972T1 (lt)
HU (2) HUE033531T2 (lt)
IL (1) IL217753A (lt)
LT (2) LT2464382T (lt)
LU (1) LUC00045I2 (lt)
MA (1) MA33469B1 (lt)
MX (2) MX355849B (lt)
MY (1) MY163003A (lt)
NO (1) NO2017054I1 (lt)
NZ (1) NZ597666A (lt)
PL (1) PL2464382T3 (lt)
PT (1) PT2464382T (lt)
RS (1) RS56146B1 (lt)
SG (1) SG178324A1 (lt)
SI (1) SI2464382T1 (lt)
TW (1) TWI409079B (lt)
UA (1) UA110096C2 (lt)
WO (1) WO2011018224A1 (lt)
ZA (1) ZA201200830B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
RS55184B1 (sr) 2010-05-31 2017-01-31 Ono Pharmaceutical Co Derivat purinona kao inhibitor btk kinaze
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP4083071A3 (en) * 2011-08-16 2023-02-22 MorphoSys AG Combination therapy with an anti-cd19 antibody and a purine analog
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
HUE031094T2 (en) 2011-11-29 2017-07-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
KR102033819B1 (ko) * 2013-06-07 2019-10-17 노르딕 나노벡터 에이에스에이 상향조절 항원 발현 방법
ES2806506T3 (es) 2014-03-25 2021-02-17 Ono Pharmaceutical Co Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
EP3281943B1 (en) 2015-04-09 2023-06-28 ONO Pharmaceutical Co., Ltd. Process for producing purinone derivative
KR20180042271A (ko) 2015-08-03 2018-04-25 잉맵 에스에이알엘 Bcma에 대응하는 단일클론 항체
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
MX2019004621A (es) 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN112399848A (zh) 2018-05-23 2021-02-23 细胞基因公司 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
NZ541503A (en) 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
JP2006528697A (ja) * 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
EP1648511A1 (en) 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
RS55723B1 (sr) * 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5315489B2 (ja) 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトIgG抗体を作製する方法
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
AU2006304886B2 (en) * 2005-10-21 2012-04-12 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
CA2749151A1 (en) * 2009-01-16 2010-07-22 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
WO2010120288A1 (en) * 2009-04-15 2010-10-21 Invista Technologies S.A R.L. Improving miscibility of otherwise immiscible compounds

Also Published As

Publication number Publication date
IL217753A0 (en) 2012-03-29
US20120315268A1 (en) 2012-12-13
ZA201200830B (en) 2012-10-31
CY1119251T1 (el) 2018-02-14
DK2464382T3 (en) 2017-07-17
WO2011018224A1 (en) 2011-02-17
AU2010281866B2 (en) 2016-05-12
UA110096C2 (uk) 2015-11-25
PL2464382T3 (pl) 2017-09-29
NZ597666A (en) 2013-10-25
US20150093376A1 (en) 2015-04-02
CN102596245A (zh) 2012-07-18
KR101425736B1 (ko) 2014-08-01
MX2012001782A (es) 2012-04-19
HUE033531T2 (hu) 2021-12-28
MX355849B (es) 2018-05-02
CL2012000391A1 (es) 2012-08-24
ES2630158T3 (es) 2017-08-18
KR20120054068A (ko) 2012-05-29
BR112012002855A2 (pt) 2016-11-01
TWI409079B (zh) 2013-09-21
HUS000498I2 (hu) 2021-03-29
NO2017054I1 (no) 2017-10-26
JP5646626B2 (ja) 2014-12-24
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
CA2769674C (en) 2018-01-23
JP2015071611A (ja) 2015-04-16
RU2012109445A (ru) 2013-09-27
HUS1700041I1 (hu) 2017-11-28
MY163003A (en) 2017-07-31
EP2464382B1 (en) 2017-05-03
EP2464382A1 (en) 2012-06-20
CN107261138A (zh) 2017-10-20
US20160166688A9 (en) 2016-06-16
LUC00045I1 (lt) 2017-11-03
SG178324A1 (en) 2012-03-29
CY2017034I2 (el) 2018-02-14
US20140044705A1 (en) 2014-02-13
AU2010281866A1 (en) 2012-02-02
CA2769674A1 (en) 2011-02-17
HK1245145A1 (zh) 2018-08-24
CR20120036A (es) 2012-04-18
JP2013501740A (ja) 2013-01-17
RS56146B1 (sr) 2017-11-30
LT2464382T (lt) 2017-07-25
MA33469B1 (fr) 2012-07-03
AR077866A1 (es) 2011-09-28
JP5963013B2 (ja) 2016-08-03
HRP20170972T1 (hr) 2017-09-22
CY2017034I1 (el) 2018-02-14
LUC00045I2 (lt) 2018-02-26
IL217753A (en) 2016-10-31
TW201110980A (en) 2011-04-01
PT2464382T (pt) 2017-06-30
JP2016222673A (ja) 2016-12-28

Similar Documents

Publication Publication Date Title
LTPA2017035I1 (lt) Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BR112013008905A2 (pt) mecanismo de dosagem e método de dosagem
DE112010001215A5 (de) Gurtaufrollersystem mit einsteuerglied
BR112014007243A2 (pt) composição, componentes e dispositivo de iluminação
ES1071902Y (es) Mecanismo de termosoldadura y precorte
FI20095999A0 (fi) Menetelmä pumppukäytön yhteydessä
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
DK2306097T3 (da) Ventilenhed med flere funktioner
ES1070576Y (es) Bionda perfeccionada
FI20095078A (fi) Menetelmä rullaimessa
TH128930B (th) สารที่มีฤทธิ์ในการฆ่าเชื้อและยับยั้งเชื้อ
FI8371U1 (fi) Järjestely taajuudenmuuttajassa
TH123099B (th) ไดไฮโดรไพราโซโลนที่ถูกแทนที่และการใช้ของมัน
TH105708B (th) ขวดพร้อมปั๊ม
UY3886Q (es) Configuración aplicada en dispensador
UY3960Q (es) Configuración aplicada en licuadora
TH103415B (th) ภาชนะ และภาชนะบรรจุโดยใช้สิ่งเดียวกันนี้
FI20096360A0 (fi) Bioliima ja puulevy
UY4071Q (es) Configuración aplicada en triciclo
TH100148B (th) ที่วางแขน
ES1069043Y (es) Recipiente perfeccionado
ITLE20080006A1 (it) Vanga con fulcro
ITBA20080004A1 (it) Easy security - cavigliera e cintura
IT1393631B1 (it) Raspa podologica con abrasivo monouso